KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Prepaid Assets (2017 - 2026)

Amneal Pharmaceuticals has reported Prepaid Assets over the past 9 years, most recently at $98.4 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 21.9% year-over-year to $98.4 million; the TTM value through Dec 2025 reached $98.4 million, up 21.9%, while the annual FY2025 figure was $98.4 million, 21.9% up from the prior year.
  • Prepaid Assets for Q4 2025 was $98.4 million at Amneal Pharmaceuticals, down from $101.5 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $232.2 million in Q2 2022 and troughed at $75.1 million in Q1 2021.
  • A 5-year average of $102.4 million and a median of $90.0 million in 2023 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: skyrocketed 123.71% in 2022 and later crashed 64.79% in 2023.
  • Year by year, Prepaid Assets stood at $110.2 million in 2021, then dropped by 6.04% to $103.6 million in 2022, then decreased by 20.16% to $82.7 million in 2023, then fell by 2.38% to $80.7 million in 2024, then grew by 21.9% to $98.4 million in 2025.
  • Business Quant data shows Prepaid Assets for AMRX at $98.4 million in Q4 2025, $101.5 million in Q3 2025, and $85.3 million in Q2 2025.